Cardiovascular safety of 5α-reductase inhibitors in people with benign prostatic hyperplasia and type 2 diabetes: a propensity-score matched analysis [0.03%]
用于治疗良性前列腺增生和2型糖尿病患者的5α-还原酶抑制剂的心血管安全性：倾向性匹配分析
Haolan Tu,Chengsheng Ju,Stuart J McGurnaghan et al.
Haolan Tu et al.
Aims: 5α-Reductase inhibitors are prescribed for the treatment of benign prostatic hyperplasia (BPH) and their use is associated with increased risk of incident type 2 diabetes. This study assessed the long-term cardiova...
The role of aetiology in determining anticoagulation effectiveness for the treatment of Left Ventricular Thrombus [0.03%]
病因在左心室血栓治疗中的抗凝有效性的作用
Johanna Jones,Holly Morgan,Krishnaraj Rathod et al.
Johanna Jones et al.
Background: Left ventricular (LV) thrombus is a severe complication of acute myocardial infarction (AMI) and chronic heart failure. While current guidelines support the use of direct oral anticoagulants (DOAC) as alternat...
Real-world evidence of finerenone in type 2 diabetes: addressing confounding and follow-up duration [0.03%]
芬格伦酮治疗2型糖尿病真实世界证据：解决混杂因素和随访时长问题
Yi-Hsien Chen,Yu-Wei Fang,Ming-Hsien Tsai
Yi-Hsien Chen
Digitoxin in Heart Failure: A Statistical Signal, or Just Noise? A Reappraisal of the DIGIT-HF Trial [0.03%]
地高辛与心力衰竭：来自DIGIT-HF试验的统计信号还是噪音？一项新的评估
Ahmed Abdelaziz,Ibrahim Halil Tanboga,Gregg C Fonarow
Ahmed Abdelaziz
Stefan Agewall
Stefan Agewall
OCEAN Trial: Rethinking Long-Term Anticoagulation After Atrial Fibrillation Ablation [0.03%]
Ocean研究：房颤射频消融术后长期抗凝的再思考
Mattia Galli,Beatrice Simeone,Sebastiano Sciarretta
Mattia Galli
Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials [0.03%]
急性ST段抬高心肌梗死冠脉内治疗的网状meta分析研究
Renzo Laborante,Emiliano Bianchini,Giuseppe Ciliberti et al.
Renzo Laborante et al.
Aims: This network meta-analysis of randomized controlled trials (RCTs) evaluates the comparative safety and efficacy of intra-coronary (IC) pharmacological and procedural treatments - on top of balloon angioplasty and st...
Antithrombotic strategies and DOAC dosing following left atrial appendage occlusion: a network meta-analysis [0.03%]
左心耳闭塞后的抗凝策略和DOAC剂量：网状meta分析
Athanasios Samaras,Paschalis Karakasis,Athanasios Feidakis et al.
Athanasios Samaras et al.
Aims: The optimal short-term antithrombotic strategy following left atrial appendage occlusion (LAAO) remains uncertain, with the need to balance thromboembolic prevention and bleeding risk presenting a critical challenge...
VESALIUS Keeps Revolutionizing Medicine: The Case of Evolocumab in Primary Prevention [0.03%]
Vesalius持续推动医学革命：以依洛尤单抗的一级预防为例
Mattia Galli,Sebastiano Sciarretta,Filippo Crea
Mattia Galli